{
  "stock": "6896.HK",
  "company": "Golden Throat Holdings",
  "start_date": "2026-02-19",
  "completion_date": "2026-02-19",
  "phases": {
    "phase1": {"status": "completed", "completed_date": "2026-02-19", "file": "phase1_data_collection.md"},
    "phase2": {"status": "completed", "completed_date": "2026-02-19", "file": "phase2_fundamental_analysis.md"},
    "phase3": {"status": "completed", "completed_date": "2026-02-19", "file": "phase3_risk_assessment.md"},
    "phase4": {"status": "completed", "completed_date": "2026-02-19", "file": "phase4_investment_decision.md"},
    "phase5": {"status": "completed", "completed_date": "2026-02-19", "file": "phase5_final_report.md"}
  },
  "recommendation": "AVOID",
  "rating": "5.25/10 - SPECULATIVE",
  "intrinsic_value_hkd": 4.07,
  "current_price_hkd": 3.18,
  "margin_of_safety": "21.9%",
  "key_risks": [
    "Management integrity concerns (failed privatization, debtor status)",
    "Patent expiration risk (2023 or 2026)",
    "Unsustainable dividend (126% payout ratio)",
    "Single product dependency (90%+ revenue)"
  ],
  "positive_factors": [
    "Strong profitability (27% net margin, 21.5% ROE)",
    "Cheap valuation (P/E 7.76x)",
    "Market leadership (#1 throat lozenge)",
    "Healthy balance sheet"
  ],
  "suitable_for": "Risk-tolerant speculators only (max 1-2% position)",
  "not_suitable_for": "Quality investors, dividend investors, ESG investors"
}
